Table 3—

Serum levels of antibodies (% B/T) specific to IAsp, specific to HI, and cross-reactive to IAsp and HI in four studies in patients with diabetes (studies 1-4) (9,10,11,12) assessed during the first treatment yearlegend

Baseline
3 Months
6 Months
9 Months
12 Months
nMeannMeannMeannMeannMean
IAsp or BIAsp 30 treatment     group
    IAsp-specific
        Study 15770.9 ± 2.85041.1 ± 3.65421.2 ± 3.64381.1 ± 3.64640.9 ± 3.2
        Study 27011.1 ± 3.56761.2 ± 3.3
        Study 3891.6 ± 4.2841.2 ± 3.5871.6 ± 4.2
        Study 41351.0 ± 2.51281.0 ± 2.6991.2 ± 2.7870.8 ± 1.9
    HI-specific
        Study 15770.8 ± 2.35040.9 ± 2.25420.8 ± 2.14380.7 ± 1.74640.7 ± 1.9
        Study 27010.7 ± 3.26760.6 ± 3.1
        Study 3890.2 ± 0.7840.3 ± 0.6870.2 ± 0.6
        Study 41350.5 ± 3.41280.6 ± 3.5990.1 ± 1.3870.2 ± 0.8
    Cross-reactive
        Study 157716.6 ± 16.350422.3 ± 19.7*54219.6 ± 17.7*43817.7 ± 17.246416.8 ± 16.5
        Study 270112.2 ± 14.067616.9 ± 15.8*
        Study 38911.0 ± 16.68413.9 ± 18.88714.1 ± 17.5*
        Study 413510.3 ± 14.012821.5 ± 21.9*9919.7 ± 18.7*8716.9 ± 17.4*
HI or BHI 30 treatment group
    Cross-reactive
        Study 127716.7 ± 16.523917.3 ± 17.325315.9 ± 16.519717.0 ± 17.420116.5 ± 16.5
        Study 235411.0 ± 13.234011.0 ± 13.3
        Study 3909.7 ± 14.7809.3 ± 13.5828.1 ± 13.1
        Study 414510.1 ± 15.413810.8 ± 16.29912.2 ± 17.49311.8 ± 16.9
  • legend

    legend Means data are means ± SD, with n = number of patients with antibody measurements at the specified time point.

  • *

    * Significant difference from baseline.